Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: Results of the Pan American collaborative retina study group at 24 months

Lihteh Wu, J Fernando Arevalo, Maria H. Berrocal, Mauricio Maia, José A. Roca, Virgilio Morales-Cantón, Arturo A. Alezzandrini, Manuel J. Díaz-Llopis

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion. Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 ± 0.63 (P <0.0001) units to 0.64 ± 0.6 units for the 2.5-mg group (P <0.0001). In the 1.25-mg group, 26 (68%) eyes gained ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 ± 140 μm to 244 ± 125 μm (P <0.0001) versus 444 ± 175 μm to 234 ± 80 μm in the 2.5-mg group (P <0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA.

Original languageEnglish (US)
Pages (from-to)1396-1403
Number of pages8
JournalRetina
Volume29
Issue number10
DOIs
StatePublished - Nov 2009

Fingerprint

Retinal Vein Occlusion
Macular Edema
Visual Acuity
Retina
Diabetic Retinopathy
Therapeutics
Injections
Bevacizumab
Endophthalmitis
Multicenter Studies
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions : Results of the Pan American collaborative retina study group at 24 months. / Wu, Lihteh; Arevalo, J Fernando; Berrocal, Maria H.; Maia, Mauricio; Roca, José A.; Morales-Cantón, Virgilio; Alezzandrini, Arturo A.; Díaz-Llopis, Manuel J.

In: Retina, Vol. 29, No. 10, 11.2009, p. 1396-1403.

Research output: Contribution to journalArticle

Wu, Lihteh ; Arevalo, J Fernando ; Berrocal, Maria H. ; Maia, Mauricio ; Roca, José A. ; Morales-Cantón, Virgilio ; Alezzandrini, Arturo A. ; Díaz-Llopis, Manuel J. / Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions : Results of the Pan American collaborative retina study group at 24 months. In: Retina. 2009 ; Vol. 29, No. 10. pp. 1396-1403.
@article{cd4f0ab61036477793d6701f4ba135cb,
title = "Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: Results of the Pan American collaborative retina study group at 24 months",
abstract = "Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion. Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 ± 0.63 (P <0.0001) units to 0.64 ± 0.6 units for the 2.5-mg group (P <0.0001). In the 1.25-mg group, 26 (68{\%}) eyes gained ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5{\%}) eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72{\%}) eyes improved ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 ± 140 μm to 244 ± 125 μm (P <0.0001) versus 444 ± 175 μm to 234 ± 80 μm in the 2.5-mg group (P <0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA.",
author = "Lihteh Wu and Arevalo, {J Fernando} and Berrocal, {Maria H.} and Mauricio Maia and Roca, {Jos{\'e} A.} and Virgilio Morales-Cant{\'o}n and Alezzandrini, {Arturo A.} and D{\'i}az-Llopis, {Manuel J.}",
year = "2009",
month = "11",
doi = "10.1097/IAE.0b013e3181bcef53",
language = "English (US)",
volume = "29",
pages = "1396--1403",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions

T2 - Results of the Pan American collaborative retina study group at 24 months

AU - Wu, Lihteh

AU - Arevalo, J Fernando

AU - Berrocal, Maria H.

AU - Maia, Mauricio

AU - Roca, José A.

AU - Morales-Cantón, Virgilio

AU - Alezzandrini, Arturo A.

AU - Díaz-Llopis, Manuel J.

PY - 2009/11

Y1 - 2009/11

N2 - Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion. Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 ± 0.63 (P <0.0001) units to 0.64 ± 0.6 units for the 2.5-mg group (P <0.0001). In the 1.25-mg group, 26 (68%) eyes gained ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 ± 140 μm to 244 ± 125 μm (P <0.0001) versus 444 ± 175 μm to 234 ± 80 μm in the 2.5-mg group (P <0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA.

AB - Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion. Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 ± 0.63 (P <0.0001) units to 0.64 ± 0.6 units for the 2.5-mg group (P <0.0001). In the 1.25-mg group, 26 (68%) eyes gained ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved ≥3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 ± 140 μm to 244 ± 125 μm (P <0.0001) versus 444 ± 175 μm to 234 ± 80 μm in the 2.5-mg group (P <0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA.

UR - http://www.scopus.com/inward/record.url?scp=73349118494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349118494&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181bcef53

DO - 10.1097/IAE.0b013e3181bcef53

M3 - Article

C2 - 19898177

AN - SCOPUS:73349118494

VL - 29

SP - 1396

EP - 1403

JO - Retina

JF - Retina

SN - 0275-004X

IS - 10

ER -